

Claims

Please amend the claims as follows:

1. (Currently Amended) A pharmaceutical aqueous suspension comprising:

a) a therapeutically effective amount of suspended solid particles in crystal form comprising ~~at least one active ingredient~~ loratadine;

b) from about 0.1 to about 0.6 % weight per volume of ~~a~~ thickener, said thickener comprising from about 0.1 to about 0.3% weight per volume of ~~a structuring agent~~ xanthan gum and from greater than 0 up to about 3 % weight per volume of ~~a swelling agent~~ pregelatinized starch;

c) ~~a uniformly dispersed nucleation inhibitor, wherein said nucleation inhibitor reduces growth rate of said active ingredient compared to suspensions not containing a nucleation inhibitor, wherein said nucleation inhibitor is polyvinylpyrrolidone, and wherein said nucleation inhibitor is present in an amount from about 1 to about 3 % weight per volume of povidone; and~~

d) ~~at least one amino polycarboxylic acid compound, wherein said amino polycarboxylic acid compound is present in an amount from about 0.01 to about 0.05 % weight per volume of~~ disodium EDTA; and

e) from greater than 0 up to about 0.1 % weight per volume of ~~a surfactant~~ polyoxyethylene sorbitan monooleate;

wherein the pharmaceutical aqueous suspension has a pH of about 3.7 to about 8; and

wherein the ~~amino polycarboxylic acid compound~~ disodium EDTA imparts improved pH and viscosity stability to the pharmaceutical aqueous suspension.

2. Canceled.

3. (Previously Presented) A pharmaceutical aqueous suspension according to claim 1, wherein the suspended solid particles have a median particle size, as measured by laser scattering, of about 1 to about 20 microns.

4. Canceled.

5. Canceled.

6. (Previously Presented) A pharmaceutical aqueous suspension according to claim 1, wherein the pharmaceutical aqueous suspension has a pH between about 3 and about 6 at room temperature.

7. (Canceled).

8. (Previously Presented) A pharmaceutical aqueous suspension according to claim 1, wherein the pH of the pharmaceutical aqueous suspension remains within about 0.2 pH units for a period of at least about four weeks when stored at a temperature of at least about 60°C.

9. (Previously Presented) A pharmaceutical aqueous suspension according to claim 1, wherein the viscosity remains constant for at least about two weeks when stored at a temperature of at least about 60°C.

10. (Previously Presented) A pharmaceutical aqueous suspension according to claim 1, wherein the viscosity remains within a range of plus or minus about 25% of its initial value for a period of at least about 8 weeks when stored at a temperature of about 60°C.

11. Canceled.

12. Canceled.

13. Canceled.

14. Canceled.

15. Canceled.

16. Canceled.

17. Canceled.

18. Canceled.

19. Canceled.

20. (Canceled).

21. (Canceled).

22. (Canceled)..

23. (Canceled).

24. (Canceled).

25. (Canceled).

26. (Canceled).

27. (Canceled).